Search

Displaying results 1431 - 1440 of 8517 in total
  1. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.

  2. Drug

    Leuprolide

    go.drugbank.com/drugs/DB00007
    ApprovedInvestigational

    [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc. … [A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels.

  3. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    [L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]

  4. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    [L53398] During studies, sugemalimab was well tolerated and has shown antitumor activity in multiple tumor types. … [L32868] Sugemalimab was under investigation in the clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma).

  5. Drug

    Cetirizine

    go.drugbank.com/drugs/DB00341
    ApprovedInvestigational

    Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal

  6. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  7. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.

  8. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

  9. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the … [A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis.